Category - Developments

Developments

Buprenorphine patient limit raised to 275

The Obama Administration will raise to 275 from 100 the limit on the number of patients with opioid addiction that certain physicians can treat with buprenorphine. The move was part of several announced by the...

July 7, 2016

Developments

FDA accepts Revive’s IND for Phase 2 bucillamine study

The FDA has accepted an IND from Revive Therapeutics (OTCQB:RVVTF; TSX-V:RVV) for a Phase 2 clinical study of bucillamine for the treatment of cystinuria. “This marks another significant milestone for Revive and...

July 6, 2016

Developments

Dipexium, Tandem Diabetes make Feltl Best Ideas list

Dipexium Pharmaceuticals (NASDAQ:DPRX) and Tandem Diabetes (NASDAQ:TNDM) have made Feltl & Co.’s Best Ideas list for the second half this year. Analyst Ben Haynor writes that top-line data for Dipexium’s two Phase 3...

July 5, 2016

Developments

Merck KGaA gets approval for Juniper’s OneCrinone in Japan

Merck KGaA of Germany (XETRA:MRK.DE) has received approval from the Japanese Ministry of Health, Labour and Welfare for Juniper Pharmaceuticals’ (NASDAQ:JNP) OneCrinone 90 mg (progesterone) for the indication of luteal...

July 5, 2016

Developments

Can-Fite unit fails Phase 2 glaucoma trial

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTC:OPLI) released top-line results from its Phase 2 clinical trial of CF101 for the treatment of glaucoma. No statistically significant differences...

July 5, 2016

Developments

Titan Pharma added to Russell 3000 index

Titan Pharmaceuticals (NASDAQ:TTNP) has been added to the broad U.S. market Russell 3000 index and the small-cap Russell 2000 index as part of Russell Investments’ annual reconstitution of its stock indexes, effective...

June 27, 2016

Developments

Cellectar shows potential against triple negative breast cancer

Cellectar Biosciences (NASDAQ:CLRB) has announced the results of the first phase of a NCI-funded Small Business Innovation Research (SBIR) Phase 1 contract for a study of CLR 125, a radiotherapeutic isotope, which may...

June 23, 2016

Developments

Anavex gets orphan drug status for infantile spasms

Anavex Life Sciences (NASDAQ:AVXL) has received FDA orphan drug designation for ANAVEX 2-73 for the treatment of infantile spasms. ANAVEX 2-73 already has orphan drug designation for the treatment of Rett syndrome. An...

June 22, 2016

Developments

Profound Medical, Royal Philips sell TULSA-PRO in Germany

Profound Medical (TSX-V:PRN) and Royal Philips have jointly sold a TULSA-PRO system to University Hospital of Cologne, the first sale in Germany, following CE Mark approval in April 2016. TULSA-PRO is an innovative...

June 21, 2016

Developments

OrbiMed joins Round B NovellusDx financing

OrbiMed will join a $10-million financing round by closely-held NovellusDx led by IntraCure, a public life science holding company, and Pontifax, a leading Israeli life sciences VC, raising the size of the round to $12...

June 21, 2016

Category - Developments

Subscribe